-
Oseltamivir Acid: From Target to Assay
2026-08-20
Oseltamivir acid is an influenza neuraminidase inhibitor whose value depends on connecting enzyme inhibition with virion-release and resistance assays. This guide adds a translational assay-design framework informed by humanized-mouse pharmacokinetic research, while distinguishing established evidence from practical recommendations.
-
Clozapine N-oxide (CNO) in Chemogenetic Research
2026-08-20
Clozapine N-oxide (CNO) is a clozapine metabolite used to activate engineered muscarinic DREADDs for controlled neuronal activity modulation. Its research value depends on receptor validation, ligand-only controls, and careful solution handling.
-
Cathepsin B inhibitor CA-074: Practical Guide
2026-08-19
CA-074 provides a selective tool for testing whether cathepsin B activity contributes to proteolysis, cancer metastasis, neurotoxic responses, or immune response modulation. It is appropriate for controlled biochemical and exploratory cellular studies, but dossier-reported selectivity and HUVEC tolerability should not be treated as proof of activity, safety, or efficacy in every model.
-
Lenalidomide (CC-5013) Myeloma Research Workflows
2026-08-19
Build reproducible Lenalidomide assays around immune restoration, angiogenesis phenotyping, and multiple myeloma combination research. This workflow also translates new DOT1L–innate immune findings into practical controls, timing studies, and troubleshooting decisions.
-
A. dahurica Pyranocoumarins Target NF-κB and MAPK
2026-08-18
A 2026 Journal of Ethnopharmacology study used activity-guided isolation to identify 35 compounds from Angelica dahurica, including a newly identified furocoumarin, and found that pyranocoumarins 2 and 3 most strongly reduced LPS-induced inflammatory responses. The work connects reduced nitric oxide and cytokine production with coordinated suppression of NF-κB and MAPK signaling, while also defining the limits of evidence from a macrophage-based in vitro model.
-
Sulfamonomethoxine Workflows for Aquaculture Research
2026-08-18
Sulfamonomethoxine supports mechanism-led studies spanning veterinary microbiology, aquaculture screening, and environmental fate analysis. This guide turns its folate-pathway activity and limited protozoan potency into practical assay, formulation, and troubleshooting decisions.
-
Clarithromycin in CYP3A Interaction Assays
2026-08-17
Build more interpretable CYP3A inhibition experiments with Clarithromycin by controlling solvent, preincubation, exposure, and orthogonal readouts. The workflow also uses dabigatran etexilate’s CYP450-independent disposition as a carefully qualified negative-control concept for separating CYP3A effects from broader assay artifacts.
-
PEG-Lipid Identity and LNP Performance In Vivo
2026-08-17
The 2025 reference study shows that PEG-lipid identity can strongly influence LNP transfection, even when PEG-lipid represents a small fraction of the formulation. Across three ionisable lipids and intramuscular, subcutaneous, and intravenous administration, DMG-PEG LNPs outperformed DSG-PEG LNPs, linking in vitro screening more closely with in vivo performance.
-
Liproxstatin-1 HCl: Reading Ferroptosis in Context
2026-08-16
Liproxstatin-1 HCl is more than a potent ferroptosis inhibitor: it is a useful perturbation tool for separating lipid-peroxidation-driven death from upstream metabolic signaling. This article connects B8221 assay design with mitochondrial calcium–GPX4 biology and explains how to interpret rescue experiments in renal and hepatic injury models.
-
ABT-888 (Veliparib): From PARP to Precision
2026-08-15
ABT-888 (Veliparib) offers a mechanistically defined way to study PARP1/2-dependent DNA repair inhibition, chemotherapy and radiation sensitization, and biomarker-led strategies in colorectal and ovarian cancer models. This thought-leadership guide connects product-level pharmacology with replication-stress biology and practical translational decision-making.
-
Bradykinin B2 Receptors and Ileal Peristalsis
2026-08-14
Chan and Rudd showed that bradykinin inhibits the peristaltic reflex of the isolated guinea pig ileum through pharmacologically defined B2 receptors, increasing the pressure threshold required to trigger propulsion. The study provides a useful framework for separating receptor-mediated effects on an integrated gut reflex from direct smooth-muscle contraction or relaxation.
-
Crystal Violet Staining Solution for Cell Assays
2026-08-14
Crystal Violet Staining Solution provides a practical endpoint for visualizing nuclei, attached cells, colonies, and surface-associated biomass. This workflow-focused guide connects cell-based assay design with clade-aware Candida auris biofilm research while emphasizing controls, quantification, and troubleshooting.
-
Diphenyleneiodonium Chloride in ROS Assays
2026-08-13
Diphenyleneiodonium chloride (DPI) is a powerful but nonselective tool for separating redox-driven effects from cAMP signaling modulation. This guide explains how to use DPI thoughtfully in oxidative stress research, including plant immunity models informed by recent citrus canker research.
-
LAG-3–TCR Proximity Suppresses T Cells and Autoimmunity
2026-08-13
A 2025 Cell study shows that LAG-3-mediated inhibition depends more on proximity to the T cell receptor than on MHC class II binding or CD4 association alone. The work links LAG-3–TCR proximity to disruption of CD3ε–Lck signaling and introduces an Fc-attenuated LAG-3/TCR bispecific antibody that suppresses T cells and reduces autoimmune disease in mice.
-
PDE-5-Silenced BMSCs in Diabetic Cardiac Injury
2026-08-12
The reference study shows that PDE-5-silenced bone marrow mesenchymal stem cells reduce high-glucose-associated myocardial fibrosis and cardiomyocyte apoptosis in neonatal rat cell models. Its key contribution is linking BMSC-mediated protection to increased cGMP/PKG signaling, while also highlighting important distinctions between fibroblast viability, extracellular-matrix remodeling, and cardiomyocyte injury markers.